Clearing Financial Model
Biotech/Pharma Startup Financials (Free Excel Download)
D2C telehealth platform delivering personalized, opioid-free chronic pain treatment via prescription compound creams shipped to patients' doors.
professionals from Deloitte
Used by professionals from
About this model
Clearing is a direct-to-consumer telehealth service for opioid-free chronic-pain treatment. Patients complete asynchronous intake, receive a physician-prescribed personalised compounding cream, and can use an app for pain tracking, guided exercise or physical therapy, and refined recommendations.
The care kit can include the compound cream, nutraceuticals, and CBD cream shipped directly to patients. Recurring shipments and telehealth consultations are the current implied revenue sources; broader pharmacy, education, group therapy, and community services are roadmap ideas rather than established revenue lines.
The company compares its ambition to what Curology did for dermatology, but the research provides no patient, revenue, pricing, conversion, or refill statistics. The model should therefore use explicit assumptions for consultations, prescription conversion, shipment cadence, product margin, clinician capacity, acquisition cost, and churn.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About Clearing
clearing.co
How to build a detailed financial model for Clearing
A complete walkthrough of the business, drivers, and assumptions behind the downloadable Clearing model - distilled from its pitch deck and publicly available information.
Product & value proposition
- Asynchronous telehealth intake → physician prescribes a personalized compounding cream (topical anti-inflammatories, local anesthetics, muscle relaxants, neuropathics, or botanicals) tailored to the patient's pain profile.
- Physical care kit (compound cream, nutraceuticals, CBD cream) shipped direct-to-door.
- Companion app: pain-level tracking, guided exercise/PT programs, iterative recommendation refinement.
- Long-term vision: integrated pain management platform adding content/education, community (peer groups), and online pharmacy (broader formulary).
- Positioning analogue: "What Curology has done for dermatology we will do for pain."
Market
- ~$45B total U.S. pain management products & pharmaceuticals market.
- $4B topical pain relief sub-segment (≈10% of total).
- 50M+ chronic pain sufferers in the U.S.; 2M new cases per year.
- 190M opioid prescriptions annually, in secular decline - creates substitution opportunity.
- 191M opioid prescriptions per year per separate appendix slide; 45% written by PCPs.
- Opioid misuse costs: $78.5B annually; 11M+ Americans misuse opioids; 17,000 deaths per year from overdose.
Revenue model
- Subscription / recurring shipment: patients receive a personalized compound cream care kit on a recurring basis (cadence not specified).
- Telehealth consultation fee: implied by asynchronous telehealth intake model; fee structure not stated.
- Product upsell: nutraceuticals (120-tablet supplement), CBD cream sold alongside compound cream.
- Future revenue lines (roadmap): content & education (group PT, group talk therapy), community features, broader online pharmacy.
Competition / moat
- Positioned in top-right quadrant of "Relevance to Pain Management" × "Personalized D2C Treatment + Pharmacy" matrix - claiming uncontested space.
- Named competitors (lower relevance or less personalized): Rightful, Zocdoc, Capsule, Cove, Hinge Health, Goodpath, Ro, Hims, Noom, Curology.
- Moat claims: personalization (data-driven treatment iteration), compound pharmacy Rx (requires telehealth Rx + compounding partner, not OTC), medical advisory board credibility (faculty from Johns Hopkins, Harvard, Hospital for Special Surgery).
- Macro tailwinds cited: telehealth acceptance post-COVID-19, rise of non-opioid treatments, availability of plug-and-play telehealth pharmacy infrastructure.
Team & funding ask / use of funds
- Founders & leadership:
- Avi Dorfman - Founder & CEO (Compass, Accretive, McKinsey)
- Dr. Jacob Hascalovici MD PhD - Co-Founder & CMO (Montefiore, Albert Einstein College of Medicine)
- Yakov Kagan - Co-Founder & Head of Growth (Uber, Bread, Codecademy)
- Jeremy Pippin - Head of Product (FanDuel)
- Alyssa Horneff - Head of Operations
- Melissa Cullens - Head of Design (Ellevest)
- Meran Liu - Head of Clinical Operations (SimpleHealth)
- Cory Goodale - Lead Engineer (Catalant)
- Medical advisory board: 6 advisors from Johns Hopkins, Harvard Medical School / MGH, Hospital for Special Surgery (team physicians for NY Rangers, NE Patriots, Boston Red Sox, Boston Bruins).
Recommended financial model
- Archetype + why: DTC subscription + telehealth P&L model (analogous to Curology / Ro / Hims). Revenue is driven by subscriber volume × ARPU (monthly subscription bundling Rx cream + nutraceuticals + app). Gross margin is shaped by compounding pharmacy COGS and fulfilment. No marketplace or SaaS ARR structure applies.
- Forecast horizon & granularity: 3 years monthly (Y1–Y2) → quarterly (Y3). Monthly cohort tracking is essential given subscription churn dynamics and iterative treatment refills.
- Key drivers & assumptions:
- Addressable chronic pain patients (U.S.): 50M; serviceable subset dependent on telehealth eligibility
- New patient starts per month:
- Monthly subscription price (ARPU):
- Monthly churn rate:
- COGS per subscriber per month:
- Gross margin target:
- Customer Acquisition Cost (CAC):
- LTV / CAC:
- Telehealth consultation fee (if separate):
- Compounding pharmacy partner cost-share:
- Headcount ramp:
- Revenue mix shift: product-only Y1 → add content/community revenue in Y2–Y3
- Scenarios (Base / Bull / Bear - which variables flex):
- Bear: slow patient acquisition (CAC spikes, conversion drops), high churn (8–10%/mo), low ARPU ($75), thin gross margin (50%) - cash-hungry, path to profitability extends beyond Y3.
- Base: steady paid-social acquisition, 6% monthly churn, $95 ARPU, 62% gross margin - reaches contribution-positive around month 18–24.
- Bull: viral/organic referral loop from community feature, churn <4%, ARPU expands via upsell (nutraceuticals, group PT), partnership distribution channel (employers, health plans).
- Required sheets / outputs:
- Subscriber cohort model (monthly new starts, cumulative actives, churn waterfall)
- Revenue build (subscription + upsell + future content/community)
- COGS & gross margin (compounding cream, nutraceuticals, fulfilment, clinical labour)
- S&M / CAC bridge (blended CAC, payback period, LTV:CAC by cohort)
- OpEx (R&D/engineering, G&A, clinical ops headcount)
- P&L summary (monthly → annual)
- Cash & runway (with funding assumption input toggle)
- Scenario toggle (Bear / Base / Bull on key drivers)
Frequently asked
Is the Clearing financial model free?+
Yes. The Clearing model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from Clearing's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Biotech/Pharma Startup Financial Models
Browse another startup in the same category.
Ada Health
AI-powered symptom assessment app and clinical decision-support platform for consumers and healthcare partners.
Affini-T
Engineered T cell therapies targeting oncogenic driver mutations (KRAS, p53) in hard-to-treat solid tumors
Alto Pharmacy
Alto Pharmacy is a tech-enabled, same-day prescription delivery pharmacy disrupting the $450B US pharmacy market via a direct-to-patient courier model and provider-facing software platform.
Aphea.Bio
Aphea.Bio is a Belgian ag-biotech company developing and commercialising microbial biologicals (biostimulants, biofungicides, bioherbicides, bioinsecticides) for row crops, targeting yield improvement and reduced synthetic input use.
Aurion Biotech
Cell therapy company developing an injectable corneal endothelial cell treatment to restore vision in patients with corneal endothelial disease.
Beckley Psytech
Clinical-stage psychedelic drug development platform advancing a pipeline of psychedelic compounds (psilocybin, 5-MeO-DMT, NCEs) as licensed pharmaceutical medicines for neuropsychiatric disorders.
BrightInsight
Regulated digital health platform-as-a-service for biopharma and medtech companies to build, launch, and maintain compliant connected-drug and medical-device software products.
Carrum Health
Value-based care marketplace connecting self-insured employers to top-tier surgical and oncology Centers of Excellence (COEs) via all-inclusive bundled payments.
